Download presentation
Presentation is loading. Please wait.
Published byMilena Sophia Medina Modified over 5 years ago
1
Fig. 1 Schematic of doxorubicin-loaded sHDL (sHDL-DOX) for chemo-immunotherapy.
Schematic of doxorubicin-loaded sHDL (sHDL-DOX) for chemo-immunotherapy. (A) sHDL-DOX is formulated by incubation of lipid-DOX with preformed sHDL. (B) The ultrasmall size and prolonged circulation of sHDL enable intratumoral delivery of DOX, followed by internalization by tumor cells and pH-responsive release of DOX in the endosomes/lysosomes. Released DOX kills tumor cells and triggers ICD, promoting up-regulation of CRT (the “eat me” signal) and release of danger signals such as HMGB1. DCs recruited to the immunogenically dying tumor cells phagocytose them, process tumor antigens, and cross-prime tumor antigen–specific T cells. Antitumor immunity primed with sHDL-DOX synergizes with immune checkpoint blockade, leading to efficient elimination of established tumors and prevention of tumor relapse. R.T., room temperature. Rui Kuai et al. Sci Adv 2018;4:eaao1736 Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.